Talk:Gilead Sciences/Archive 1

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Allegations

Is there anything serious in the allegation that the bird flu "imminent pandemic" which has up to now killed some dozen people in about a decade is hyped in order to fill Rumsfeld's wallet? ROGNNTUDJUU! 22:54, 17 March 2006 (UTC)

What do you mean by "serious"? If you want to know whether this allegation can be backed up by cold, hard facts, then the answer is "No." --Felixkrull 18:22, 11 April 2006 (UTC)

Efavirenz is not a BMS product. It's produced by Merck.NYDCSP 22:04, 4 May 2007 (UTC)

Efavirenz is marketed in the USA by BMS under the trade name SUSTIVA [1]. It is marketed by one of the Merck subsidiaries in Europe. Gilead did a deal with BMS to combine efavirenz with Truvada to make Atripla in the USA [2], but does not have a similar agreement with Merck for the rest of the world. G716 19:49, 3 June 2007 (UTC)

Financial Highlights

Do we need this section?

  • Quickly out of date
  • Not straightforward to update in the format it is in
  • Info is already in the info box
  • More extensive and up to date info is easily available on the web
  • Not really encyclopedic content

G716 02:23, 23 June 2007 (UTC)

Removed the following outdated info: 

Fiscal year 2005 (ended Dec. 31, 2005)[3][4]

			GAAP				NON-GAAP
Total Revenues		$2.028 billion 	        	$2.028 billion
Net Product Sales	$1.809 billion 	        	$1.809 billion
Total Expenses		$917.3 million 	        	$917.3 million
Net Income		$813.9 million 	                $788.8 million
EPS			$1.72 per diluted share 	$1.66 per diluted share
Cash and Equivalents	$707.0 million          	

Stock Split (2-for-1)	September 2004 (most recent)

G716 06:04, 6 July 2007 (UTC)

It would be nice to know what the exchange rate was for the merger of Nexstar into Gilead. I would guess it was one share of GILD for every 2.65 shares of Nexstar, but does anyone know for sure? —Preceding unsigned comment added by 69.136.112.150 (talk) 16:01, 22 July 2008 (UTC)

DaunoXome

DaunoXome was sold to Diatos in 2006.

"Diatos Announces Acquisition of Specialty Cancer Product DaunoXome® from Gilead" (pdf) (Press release). Diatos SA. 2006-03-28. Retrieved 2007-08-13. {{cite press release}}: Check date values in: |date= (help)

--G716 03:30, 14 August 2007 (UTC)

Products on the market

The text says Gilead has 12 products on the market, but only 11 are shown in the table. Elsewhere, the article says there are 11. Which statement is right?Fconaway (talk) 00:57, 21 October 2009 (UTC)

Removed Gstock link

I removed the Gstock link about Gilead's stock performance. It's repetitive; the Yahoo link and the Answers.com link both provide extensive information on Gilead, including a year-long stock price and volume chart, and they do this without requiring registration, and without requiring readers to agree to a four thousand, three hundred and seventy six word Terms of Service. —Preceding unsigned comment added by 67.193.202.168 (talk) 02:41, 13 November 2009 (UTC)

Vandalism of the board of directors list

Ficticious names have been added. — Preceding unsigned comment added by Chamblis (talk • contribs) 04:10, 13 February 2012 (UTC)

Pipeline

the following is outdated and is based in part on a ref from 2008 and the rest from their website or other poor/SPS sources, generally. this should not be here per WP:NOTNEWS and WP:NOTWEBHOST:

Product pipeline

Gilead's pipeline[1] focuses on HCV, HIV, cardiovascular and respiratory disorders.

Drug Name Description Potential Indication Testing Phase[2]
Cobicistat/Tybost (formerly GS-9350) Pharmacokinetic enhancer HIV/AIDS submitted for US + EU approval
Elvitegravir (formerly GS-9137) Integrase inhibitor HIV/AIDS submitted for US + EU approval
Single Tablet Regimen elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide HIV/AIDS Phase III
Single Tablet Regimen darunavir, cobicistat, emtricitabine, and tenofovir alafenamide HIV/AIDS Phase II
Single Tablet Regimen sofosbuvir and ledipasvir Hepatitis C Phase III
GS-5816 pan-genotypic NS5A inhibitor Hepatitis C Phase II
GS-9451 NS3 Protease inhibitor Hepatitis C Phase II
GS-9669 non-nucleoside NS5B inhibitor Hepatitis C Phase II
Ledipasvir (formerly GS-5885) NS5A inhibitor Hepatitis C Phase III
GS-9620 TLR-7 agonist Hepatitis C/Hepatitis B Phase I
Tenofovir alafenamide (TAF) (formerly GS-7340) nucleotide reverse transcriptase inhibitor Hepatitis B Phase I
GS-4774 Tarmogen T cell immunity stimulator Hepatitis B Phase I
Simtuzumab (formerly GS-6624) Humanized monoclonal antibody Liver Fibrosis/Idiopathic Pulmonary Fibrosis/Myelofibrosis/Pancreatic Cancer Phase II
GS-9973 Syk inhibitor B-Cell Malignancies Phase II
GS-9820 (formerly CAL-120) PI3K delta inhibitor Lymphoid Malignancies Phase II
GS-5745 MMP9 mAb inhibitor Ulcerative Colitis/Solid Tumors Phase I
Momelotinib Janus kinase inhibitor Myelofibrosis Phase II
Ranolazine Late sodium current inhibitor Coronary Artery Disease/Diabetes Phase III
Single Tablet Regimen Ranolazine and Dronedarone Paroxysmal Atrial Fibrillation Phase II
GS-6615 Ischemic Heart Disease and Arrhythmias Phase I
GS-5806 Respiratory Syncytial Virus Phase II
Terminated from product pipeline

Gilead no longer develops these products[1]

Drug Name Description Potential Indication Development Terminated at
Aztreonam inhalation solution Bronchiectasis Phase II
GS-9256 Protease inhibitor Hepatitis C Phase II
GS-9310/11 inhaled fosfomycin/tobramycin Cystic Fibrosis/Chronic Obstructive Pulmonary Disease Phase II
GS-9667 (formerly CVT-3619) Partial A1 adenosine agonist Diabetes/Dyslipidemia ?
GS-6201 (formerly CVT-6883) A2B adenosine antagonist Pulmonary diseases Phase I
GS-6620 Nucleotide polymerase inhibitor Hepatitis C Phase I
GS-9411 Epithelial sodium channel blocker Pulmonary diseases Phase I
Tegobuvir (formerly GS-9190) Non-nucleoside polymerase inhibitor Hepatitis C Phase II
Cicletanine Antihypertensive Pulmonary arterial hypertension Phase II
CVT-10216 ALDH-2 inhibitor Drug addiction preclinical[3]
Tecadenoson Selective A1 adenosine receptor Atrial fibrillation ?
Perfan Enoximone Heart failure Phase III[4]
GS-9219 Nucleotide analogue Non-Hodgkin’s lymphoma and Chronic lymphocytic leukemia Phase I[5]
GS-8374 Protease inhibitor HIV/AIDS preclinical[6]
GS-424020 Prodrug of Desisobutryl-ciclesonide and salmeterol Asthma and Chronic obstructive pulmonary disease preclinical[7]
GS-9148 Nucleotide analog, phosphonomethoxy-2'-fluoro-2', 3'-dideoxydidehydroadenosine HIV/AIDS preclinical[8]
GS-9131 Prodrug of GS-9148 HIV/AIDS preclinical[8]
GS-9224 Integrase inhibitor HIV/AIDS preclinical[9]
CAL-263 PI3K Delta selective inhibitor inflammatory diseases Phase I
GS-9820 (formerly CAL-120) PI3K Delta selective inhibitor inflammatory diseases preclinical
CAL-129 PI3K Delta selective inhibitor inflammatory diseases and oncology preclinical
CAL-253 PI3K Delta selective inhibitor inflammatory diseases and oncology preclinical


References

  1. ^ a b "Gilead Product Pipeline". Retrieved 2013-09-12.
  2. ^ "2009 Gilead 10-K". United States Securities and Exchange Commission. Retrieved 2011-01-16.
  3. ^ Fox, Maggie (2010-08-22). "Kudzu extract may treat cocaine". Reuters. Retrieved 2011-01-16.
  4. ^ "The Studies of Oral Enoximone Therapy in Advanced Heart Failure". ClinicalTrials.gov. 2011-01-28.
  5. ^ "2008 Gilead 10-K". United States Securities and Exchange Commission. Retrieved 2011-01-16.
  6. ^ "GS-8374, a novel HIV protease inhibitor, does not alter glucose homeostasis in cultured adipocytes or in a healthy rodent model system". American Society for Microbiology. Retrieved 2011-01-29.
  7. ^ "In Vitro Metabolism Of GS-424020, A Novel Mutual Prodrug Of Salmeterol And Desisobutryl-ciclesonide, BY AIR-liquid Interface HUMAN BRONCHIAL EPITHELIAL CELLS" (PDF). American Journal of Respiratory and Critical Care Medicine. Retrieved 2011-01-29.
  8. ^ a b "Update on Gilead Sciences Anti-HIV Development Programs". Journal of Acquired Immune Deficiency Syndromes. Retrieved 2011-01-29.
  9. ^ "Abstract, 2011 Conference on Retroviruses and Opportunistic Infections". Conference on Retroviruses and Opportunistic Infections. Retrieved 2011-02-21.

-- Jytdog (talk) 18:28, 10 November 2016 (UTC)

hiv cure?

I was invited to a dinner one day and there was a speaker who said that one day there will be a vaccination for people not to contract HIV; but that there would not be a cure for the already infected. This speaker represents Gilead. How true is this statement I wonder? —Preceding unsigned comment added by 99.162.27.248 (talk) 09:00, 10 March 2009 (UTC)

   Interesting talk contrib, from an IP user & with info from a source left profoundly anon; sounds like a great way to manipulate Gilead stock prices. "Beware of geeks baring gifts".
--Jerzy•t 19:37, 23 November 2016 (UTC)

External links modified

Hello fellow Wikipedians,

I have just modified one external link on Gilead Sciences. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

checkY An editor has reviewed this edit and fixed any errors that were found.

  • If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
  • If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 23:23, 11 January 2017 (UTC)

Impressive importation of Gilead's website

Hm, I had removed this back in November, and here it is back again.

These tables are impressive importations of Gilead's website but this we don't rebuild company websites in Wikipedia.

This is not encyclopedic content, in my view. Not (as in WP:NOT) what we do here. It is definitely something that can be done here.

Am well aware that company websites always include this content. Of course they do.

Ref #1 is fake - the FDA drug search page. Ref #2 only covers 13 products and is of course an SEC filing. Ref #3 is.. the company website.

So this is entirely OR. A work of love, but not valid here in WP.

Product portfolio

Gilead has 21 products on the market.

Product Portfolio
Brand Name Drug Name(s) Indication Date Approved (USA)[1] Marketing Partner(s) U.S. Patent Expiration[2] European Patent Expiration[2]
AmBisome liposomal amphotericin B fungal infection, cryptococcal meningitis, Aspergillus, Candida, Cryptococcus infections 1997-08-11 Astellas Pharma(USA)Rapiscan(EU) 2016 expired
Atripla tenofovir, emtricitabine, and efavirenz HIV, AIDS 2006-07-12 Bristol-Myers Squibb 2021 2018
Cayston Aztreonam Cystic Fibrosis 2010-02-22 2021 2021
Descovy Emtricitabine/tenofovir alafenamide 2016-04-04
Epclusa Velpatasvir/sofosbuvir Hepatitis C 2016-06-28
Complera/Eviplera tenofovir, emtricitabine, and rilpivirine HIV, AIDS 2011-08-10 Johnson and Johnson  
Emtriva emtricitabine HIV, AIDS 2003-07-02   2021 2016
Flolan epoprostenol sodium pulmonary hypertension 1995-09-20 GlaxoSmithKline expired expired
Genvoya Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 2015-11-05
Harvoni sofosbuvir, ledipasvir Hepatitis C 2014-10-10
Hepsera adefovir dipivoxil hepatitis B (HBV) 2002-09-20   2014 2011
Letairis ambrisentan Pulmonary arterial hypertension 2007-06-15 GlaxoSmithKline 2015 2015
Lexiscan regadenoson myocardial perfusion imaging 2008-04-10 Astellas 2019 2020
Macugen pegaptanib sodium solution age-related macular degeneration 2004-12-17 OSI and Pfizer 2017 2017
Odefsey Emtricitabine/rilpivirine/tenofovir alafenamide 2016-03-01
Ranexa ranolazine angina 2006-01-27 Hoffmann–La Roche 2019 2019
Sovaldi sofosbuvir Hepatitis C 2013-12-06
Stribild elvitegravir, cobicistat, emtricitabine, tenofovir HIV, AIDS 2012-08-27
Tamiflu oseltamivir phosphate influenza 1999-10-27 Hoffmann–La Roche 2016 2016
Truvada emtricitabine and tenofovir HIV, AIDS 2004-08-02   2021 2018
Tybost cobicistat HIV, AIDS 2013-09-25 (EU), 2014-09-24 (US)
Vemlidy Tenofovir alafenamide 2016-11-10
Viread tenofovir HIV, AIDS, hepatitis B 2001-10-26   2017 2018
Vistide cidofovir CMV retinitis 1996-06-26 Pfizer expired expired
Vitekta elvitegravir HIV, AIDS 2013-09-25 (EU), 2014-09-24 (US)
Zydelig idelalisib oncology, lymphoma 2014-07-23
Pipeline

Phase II and III drugs currently in development include:[3]

References

  1. ^ "Drugs@FDA: FDA Approved Drug Products". Food and Drug Administration. Retrieved 2011-01-15.
  2. ^ a b Gilead Sciences (2010-03-01). "2009 Form 10-K Annual Report". SEC. Retrieved 2011-01-15.
  3. ^ http://www.gilead.com/research/pipeline

-- Jytdog (talk) 14:44, 31 August 2017 (UTC)

1992 prospectus

Would love to find an RS for their IPO. SEC EDGAR only goes back to 94... Scribd is not OK. 15:11, 31 August 2017 (UTC)

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Gilead_Sciences/Archive_1&oldid=1062906774"